Bioventix Announcements

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has today posted its Annual Report for the year ended 30 June 2023 together with a Notice of Annual General Meeting (“AGM”) and Form of Proxy to shareholders that have elected to receive documentation in hard copy format. The documents will also be available to download in PDF format below:

30 June 2023 Annual Report

Notice of AGM

Form of Proxy

The Company’s AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on Thursday 7 December 2023 at 2.00pm.

For further information please contact:

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Bioventix plc (BVXP) announces its audited results for the year ended 30 June 2023

Highlights:
• Revenue up 9% to £12.82 million (2022: £11.72 million)
• Profit before tax up 9% to £10.13 million (2022: £9.28 million)
• Cash at year end of £5.7 million (30 June 2022: £6.1 million)
• Second interim dividend of 90p per share (2022: 74p)
• Total dividends 152p per share (2022: 152p)

Click here to download the full report.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Bioventix plc

(“Bioventix” or the “Company”)

Board Appointment

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics is delighted to announce that it has appointed Joanne (Jo) Pisani to the Board, as an independent Non-Executive Director, with immediate effect. Jo will chair the Company’s Audit Committee.

Jo is a chartered engineer with a distinguished background in the Pharmaceutical, Life Sciences and Biotech sectors. She has held roles at GSK and BP in strategy, commercial and operational functions before working in strategic consultancy. She led PwC’s UK Pharmaceutical and Life Sciences practice, assisting clients with developing strategy, designing and implementing transformational change and completing M&A transactions.

Jo is a passionate supporter of critical public health issues, such as tackling dementia, rare diseases and anti-microbial resistance. She focuses on supporting charities, universities and business start-ups. She is chair of Birmingham’s Precision Health Technology Accelerator and also chairs the Advisory Board for London’s MedCity. She serves on the boards of the UK Dementia Research Institute, LifeArc, The RSA Group, London and Partners and Beacon.  She is also a Non-Executive Director and strategic advisor to biotech companies in the UK, Finland and Spain

Ian Nicholson, Chairman, commented: “The Board is delighted to welcome Jo to Bioventix. She brings considerable leadership and strategic experience in Life Sciences and biotech businesses, large and small, that is highly relevant to Bioventix and the opportunities being addressed by the Company. I am confident that she will add considerable value to the Company.”

For further information please contact:

Regulatory disclosures

INFORMATION REQUIRED UNDER RULE 17 AND SCHEDULE 2, PARAGRAPH (G) OF THE AIM RULES FOR COMPANIES (“AIM RULES”)

There is no further information to be disclosed in relation to the director appointment pursuant to Rule 17 and Schedule 2, paragraph (g) of the AIM Rules.